Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 4/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | MAP4K1 | Q92918 | 9/20 | 0.43 |
| ▸ | IL2 | P60568 | 3/20 | 0.43 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.39 |
| ▸ | TNIK | Q9UKE5 | 4/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17273459 | 0.92 | ALK (0.56) | ALKBRD4MAP4K1IL2MAP3K11 | |
| Hydrochloric Acid SCHEMBL15557566 | 0.92 | ALK (0.55) | ALKBRD4MAP4K1IL2MAP3K11 | |
| SCHEMBL15599271 | 0.91 | ALK (0.56) | ALKMAP4K1IL2MAP3K11 | |
| SCHEMBL15599359 | 0.91 | ALK (0.56) | ALKMAP4K1IL2MAP3K11TNIK | |
| SCHEMBL15599469 | 0.89 | ALK (0.69) | ALKMAP4K1IL2TNIK | |
| SCHEMBL15599391 | 0.88 | ALK (0.59) | ALKMAP4K1IL2TNIK | |
| SCHEMBL17273378 | 0.88 | ALK (0.51) | ALKBRD4MAP4K1IL2MAP3K11 | |
| SCHEMBL15599468 | 0.88 | ALK (0.58) | ALKMAP4K1IL2MAP3K11TNIK | |
| SCHEMBL15599378 | 0.85 | ALK (0.56) | ALKMAP4K1IL2TNIK | |
| SCHEMBL15599274 | 0.84 | ALK (0.67) | ALKMAP4K1IL2MAP3K11TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353107-B2 | 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-05-31 | — | — | US | disclosed |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | Um Pharmauji Sdn. Bhd. (MY) | 2015-11-26 | — | — | US | disclosed |
| WO-2014006554-A1 | 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | MAP3K3, MAP3K1, MAP3K6 | ALK 408/4885BRD4 639/4885MAP4K1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.